Can I Take Rhodiola with Low-Dose Naltrexone?

No published trial has tested rhodiola rosea and compounded low-dose naltrexone (LDN) together, so there is no direct safety data on this specific pairing. Naltrexone (generic; the same molecule sold as ReVia or Vivitrol at 50 mg for opioid and alcohol use disorder) is not known to share a metabolic pathway with rhodiola's active constituents in a way that would cause a clinically meaningful pharmacokinetic interaction. The realistic concern is pharmacodynamic and theoretical: rhodiola has weak, dose-dependent effects on monoamine signaling that overlap conceptually with LDN's opioid-rebound mechanism, and this overlap has not been studied in humans taking both agents. For most people without other serotonergic medications or mood disorders, the combination is plausible to use with routine monitoring, but "plausible" is not the same as "established safe."

What each substance is, and why they might interact at all

Low-dose naltrexone (LDN) uses the same active molecule as standard-dose naltrexone but at roughly one-tenth to one-thirtieth the dose, usually 1.5 to 4.5 mg at bedtime. At 50 mg, naltrexone produces sustained opioid receptor blockade for about 24 hours, which is the FDA-approved use for opioid and alcohol dependence. At micro-doses, researchers have proposed a different mechanism: brief nightly receptor blockade followed by a rebound in endogenous opioid signaling and possible modulation of microglial activation. This is an off-label use. It is not FDA-approved, and the mechanism, while biologically plausible and studied in small trials for conditions like fibromyalgia, is not settled science.

Rhodiola rosea is a plant used traditionally as an adaptogen, marketed as a supplement to support resilience to physical and psychological stress. Its two most-discussed constituent classes are rosavins (considered relatively specific to R. rosea) and salidroside (shared with other Rhodiola species). As a dietary supplement, rhodiola is not FDA-approved for any medical indication; supplement manufacturers cannot legally make disease claims, and product standardization varies by brand.

The reason these two substances come up together is that both are proposed to touch overlapping biological systems: monoamine neurotransmission (serotonin, dopamine, norepinephrine) and the hypothalamic-pituitary-adrenal (HPA) stress axis. Overlap in mechanism is not the same as a demonstrated interaction.

Is there a known pharmacokinetic interaction?

Naltrexone is metabolized mainly through non-CYP pathways (cytosolic reduction to 6-beta-naltrexol), with only a secondary role for CYP3A4. Laboratory studies on rhodiola extracts have examined effects on several cytochrome P450 enzymes, including CYP3A4 and CYP2D6, generally at concentrations well above what oral supplement doses would be expected to produce in human plasma. Based on this mechanistic picture, a clinically significant pharmacokinetic interaction, meaning rhodiola changing naltrexone blood levels or vice versa, is unlikely at typical supplement doses. This conclusion is inferred from how each substance is metabolized rather than confirmed by a human interaction study, and it should be treated as a reasonable inference rather than a settled fact.

What is the pharmacodynamic concern, specifically?

The plausible, unproven concern has three components:

Monoamine oxidase activity. Laboratory (in vitro) studies have reported that rhodiola extracts weakly inhibit MAO-A and MAO-B enzymes, but at concentrations far higher than what oral dosing is thought to achieve in the bloodstream. Most pharmacologists consider the clinical MAO-inhibiting effect of standard oral rhodiola doses to be low, though it has not been ruled out entirely, particularly in people who metabolize drugs more slowly.

Monoamine reuptake effects. Animal studies have suggested that salidroside may modestly increase synaptic dopamine and serotonin availability, an effect sometimes compared, loosely, to a weak SNRI-like action. These are rodent behavioral studies, not human pharmacology data, and the comparison to prescription antidepressants overstates the likely potency.

HPA-axis and cortisol effects. Rhodiola has been studied for its effect on cortisol output under acute stress. LDN is separately proposed to influence stress-axis regulation through its effects on opioid and inflammatory signaling. If both agents nudge cortisol and mood-regulating systems in the same direction, the combined effect could in theory be additive, whether that shows up as benefit (better stress tolerance) or as unwanted over-activation (agitation, insomnia) is not established.

None of this constitutes a documented case of harm from combining the two. It is a mechanistic argument for caution and monitoring, not a demonstrated risk.

Evidence-status interaction assessment

Before relying on any specific enzyme, dose-response, or percentage figure from older summaries of this topic, a clinician or pharmacist should re-verify the number against the primary paper rather than trusting a secondhand citation, since several figures circulating in consumer health content on this topic have proven difficult to trace back to a verifiable source.

Who should involve a prescriber before combining these

• Anyone taking an SSRI, SNRI, tramadol, a triptan, or a pharmaceutical MAO inhibitor. Adding a supplement with any monoamine-modulating activity increases the number of agents contributing to serotonergic tone, and cumulative serotonergic load is a recognized clinical concern even when each individual agent's contribution is small.
• Anyone with bipolar disorder, especially bipolar II or cyclothymia. Rhodiola's stimulant-adjacent, monoamine-elevating properties carry a theoretical risk of triggering hypomania. LDN has anecdotal associations with mood elevation in some patients. Neither has been formally studied for mania risk in bipolar patients, which argues for psychiatric involvement rather than self-directed trial.
• Anyone who is pregnant or breastfeeding. Neither LDN nor rhodiola has an established safety profile in pregnancy or lactation; both should be treated as unstudied in this population rather than presumed safe.
• CYP2D6 poor metabolizers, a genetic subgroup more common in some populations, may theoretically process certain naltrexone metabolites differently, though naltrexone itself is not primarily CYP2D6-dependent. This is a minor consideration and mainly relevant if unusual side effects appear.

Practical spacing and monitoring, in general terms

A common-sense approach used by prescribers familiar with LDN is to separate the two substances in time rather than to avoid the combination outright: rhodiola in the morning, LDN at bedtime, giving roughly 8 to 12 hours of separation. This does not eliminate a pharmacodynamic overlap but reduces the chance that peak effects of each substance coincide.

If starting rhodiola on top of an established LDN routine, going slowly and watching for a specific set of symptoms over the first few weeks is the standard-of-caution approach: changes in sleep quality or dream intensity, new anxiety or irritability, unexpected mood elevation, and headache. If any of these appear, stopping the new addition and discussing it with the prescriber before resuming is more prudent than pushing through.

Seek urgent medical evaluation if a fast heart rate, confusion, fever, muscle twitching, or diarrhea develop together, particularly in someone taking other serotonergic medications. These are recognized features of serotonin toxicity in general, though it has not been documented specifically from rhodiola plus LDN in isolation.

This article does not provide an individualized dosing recommendation. Starting doses, titration speed, and whether to combine these substances at all should be set by the prescriber and pharmacist managing the compounded LDN prescription, who can review the full medication list.

What is genuinely unknown here

• Whether rhodiola changes the clinical response to LDN, for better or worse, in any condition LDN is used for off-label (fibromyalgia, autoimmune disease, chronic fatigue, and others).
• Whether the combination changes the rate of LDN's known side effects, such as vivid dreams or initial nausea.
• Whether any dose threshold of rhodiola meaningfully changes the risk picture.
• Whether long-term combined use has different implications than short-term use.

Absence of trial data on the combination is not evidence that the combination is dangerous. It means the honest answer to "is this safe together" is "probably, for most people, based on how each substance behaves separately," not "yes, confirmed."